Boston Scientific Corporation (BSX) has been upgraded to a 'Strong Buy' rating, driven by the view that market overreaction has created an attractive entry point for long-term investors. The stock currently trades at a forward P/E ratio of 13.1, which is significantly below its historical average despite demonstrating robust profitability and solid results in the second quarter of 2026. The company's growth trajectory is being reshaped by specific segment dynamics. While headwinds persist in the WATCHMAN and electrophysiology sectors, these are being effectively offset by strong momentum in Interventional Cardiology and Vascular Therapies. This strategic balance suggests resilience against sector-specific challenges while capitalizing on core business strengths. Future growth prospects for BSX are supported by the recent Penumbra acquisition and the positioning of its IVL product line, which are expected to drive renewed expansion. These developments are underpinned by a strong balance sheet and favorable trends within the broader medical device sector, reinforcing the company's long-term investment thesis.